Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84008 | 0.89 | FFAR1 (0.43) | SYKADRB2ADRB1ADRB3KDM5A | |
| Acetic Acid SCHEMBL69063 | 0.87 | FFAR1 (0.41) | SYKADRB2ADRB1ADRB3KDM5A | |
| SCHEMBL2085623 | 0.84 | CYP4F2 (0.41) | SYKCYP4F2CYP4A11CYP4Z1NAMPT | |
| SCHEMBL2086788 | 0.84 | CYP4F2 (0.41) | SYKCYP4F2CYP4A11CYP4Z1NAMPT | |
| SCHEMBL2083895 | 0.83 | CYP4F2 (0.43) | SYKCYP4F2CYP4A11CYP4Z1NAMPT | |
| SCHEMBL68850 | 0.81 | RAB9A (0.38) | SYKADRB2ADRB1HPGD | |
| SCHEMBL68137 | 0.81 | SYK (0.41) | SYKCYP4F2CYP4A11CYP4Z1NAMPT | |
| SCHEMBL1750295 | 0.80 | PPARA (0.42) | — | |
| SCHEMBL1750142 | 0.79 | PPARA (0.42) | — | |
| SCHEMBL4221432 | 0.77 | KDM5A (0.38) | KDM5AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303549-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RES & DEV (FR) | 2013-11-14 | — | — | US | disclosed |
| US-8513297-B2 | Biaromatic compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-08-20 | — | — | US | disclosed |
| US-20120121527-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARy TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-05-17 | — | — | US | disclosed |
| US-8129416-B2 | Biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-03-06 | — | — | US | disclosed |
| EP-1814871-B1 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-20080027077-A1 | Novel biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-31 | — | — | US | disclosed |
| EP-1814871-A2 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006053791-A2 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027077-A1 | Novel biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | SYK 4588/4885CYP4F2 457/4885CYP4A11 233/4885 |
| US-20130303549-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | PPARG, PPARD, PPARA | SYK 4191/4885CYP4F2 427/4885CYP4A11 257/4885 |
| US-20120121527-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARy TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | PPARG, PPARD, PPARA | SYK 4191/4885CYP4F2 427/4885CYP4A11 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.